Resources
News

Verrill Dana Welcomes Health Care Attorney Rachel Weisblatt

October 3, 2017 Press Releases

(October 3, 2017) – Verrill Dana is pleased to welcome health care attorney Rachel Weisblatt to the firm's Boston, Massachusetts office.

As a member of Verrill Dana's Health Care Group, Weisblatt's practice will focus on a wide variety of transactional, regulatory and litigation matters.

Previously, Weisblatt worked as an associate in the Public Finance Group of Mintz Levin. While there, she also served as bond counsel, underwriter's counsel and borrower's counsel for tax-exempt and taxable financings related to health care, housing, higher education and economic development, with a focus on 501(c)(3) health care financings.

Weisblatt received her law degree from Boston College Law School and earned her bachelor's degree from McGill University. While in law school, she served as a regulatory practice extern at the Massachusetts Health Policy Commission and interned at the Massachusetts Attorney General's Office in the Health Care Division. She also served as a Staff Writer for the Boston College Law Review.

About Verrill Dana's Health Care Group: Verrill Dana's Health Care Group serves a wide variety of organizations in the healthcare industry and related professions with respect to a wide range of matters including academic and biomedical research, accountable care organizations and managed care, eHealth and health information technology, HIPAA/HITECH privacy and security, Medicare/Medicaid and third-party reimbursement, mergers and acquisitions, and regulatory compliance. Learn more about the group at www.verrilldana.com/healthcare.

Firm Highlights

Publication/Podcast

EU-U.S. Privacy Shield Invalidated: Does Your Company Have a Plan B?

On Thursday, July 16, 2020, the Court of Justice of the European Union (“CJEU”) invalidated the EU-U.S. Privacy Shield (“Privacy Shield”) in Data Protection Commissioner v. Facebook Ireland and Maximillian Schrems (Case C-311/18...

Matter

Conflicts of Interest

Reviewed medical center's systems, policies and procedures for identifying, assessing, and managing investigator and institutional conflicts of interest.

News

Michael K. Fee to Lead Verrill’s Nationally-Recognized Health Care and Life Sciences Practice Amidst Recent Changes

(August 31, 2020) – Verrill is pleased to announce Michael K. Fee as the new leader of Verrill’s nationally-recognized Health Care & Life Sciences Group. The Group has a long history of representing a...

News

Nearly 80 Verrill Attorneys Recognized by Best Lawyers® 2021, Including a Dozen Named Lawyers of the Year

(August 24, 2020) – Nearly 80 Verrill attorneys were recognized as "Best Lawyers" by Best Lawyers® 2021 , including 12 attorneys named “Lawyer of the Year,” a distinguished recognition for only a single lawyer...

Publication/Podcast

FDA Updates its Guidance on Conducting Clinical Trials During COVID-19 Public Health Emergency

On April 16, 2020, the U.S. Food & Drug Administration (“FDA”) again updated its guidance on the “Conduct of Clinical Trials of Medical Products during COVID-19 Public Health Emergency,” adding seven new questions and...

News

38 Verrill Attorneys, Across Four Offices, Recognized in 2020 Chambers & Partners Guide

(April 27, 2020) – Verrill has been rated as a Leading Firm in a total of ten categories and subcategories as evaluated by London-based Chambers & Partners , one of the world's most respected...

Matter

Multi-Site Global Research

Developed and negotiated site and coordinating center agreements in connection with a multi-site, international, National Institutes of Health (NIH)-funded study, and advised on regulatory issues related to the conduct of the study and subsequent...

Publication/Podcast

News Flash: HHS Issues Statement Removing Premarket Review Requirements for Laboratory Developed Tests (“LDTs”), Including COVID-19 LDTs

What happened? On August 19, 2020, the U.S. Department of Health and Human Services (“HHS”) issued a single paragraph statement rescinding U.S. Food and Drug Administration (“FDA”) guidance documents concerning premarket review of Laboratory...

Publication/Podcast

FDA Issues Guidance on IRB Review of Non-Emergency Individual Patient Expanded Access Requests for Investigational Drugs and Biological Products to Treat COVID-19

Prompted by a substantial increase in requests for individual patient access to investigational drugs and biologics to treat COVID-19, the U.S. Food & Drug Administration (“FDA”) issued guidance on June 2, 2020 that outlines...

Matter

European Union GDPR—Institution

Counseled a preeminent health system and academic medical center on its compliance with the European Union General Data Protection Regulation (GDPR) in relation to its clinical and research activities, including its international research studies...